全文获取类型
收费全文 | 2101篇 |
免费 | 204篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 61篇 |
妇产科学 | 21篇 |
基础医学 | 288篇 |
口腔科学 | 98篇 |
临床医学 | 196篇 |
内科学 | 544篇 |
皮肤病学 | 46篇 |
神经病学 | 220篇 |
特种医学 | 111篇 |
外科学 | 159篇 |
综合类 | 52篇 |
预防医学 | 143篇 |
眼科学 | 18篇 |
药学 | 270篇 |
中国医学 | 7篇 |
肿瘤学 | 82篇 |
出版年
2021年 | 17篇 |
2019年 | 30篇 |
2018年 | 36篇 |
2016年 | 16篇 |
2015年 | 34篇 |
2014年 | 30篇 |
2013年 | 50篇 |
2012年 | 73篇 |
2011年 | 71篇 |
2010年 | 39篇 |
2009年 | 51篇 |
2008年 | 60篇 |
2007年 | 76篇 |
2006年 | 79篇 |
2005年 | 67篇 |
2004年 | 77篇 |
2003年 | 78篇 |
2002年 | 50篇 |
2001年 | 74篇 |
2000年 | 65篇 |
1999年 | 74篇 |
1998年 | 46篇 |
1997年 | 36篇 |
1996年 | 48篇 |
1995年 | 22篇 |
1994年 | 27篇 |
1993年 | 33篇 |
1992年 | 56篇 |
1991年 | 61篇 |
1990年 | 56篇 |
1989年 | 54篇 |
1988年 | 60篇 |
1987年 | 60篇 |
1986年 | 62篇 |
1985年 | 65篇 |
1984年 | 49篇 |
1983年 | 27篇 |
1982年 | 19篇 |
1981年 | 27篇 |
1980年 | 19篇 |
1979年 | 37篇 |
1978年 | 32篇 |
1977年 | 18篇 |
1976年 | 19篇 |
1975年 | 22篇 |
1974年 | 25篇 |
1972年 | 19篇 |
1970年 | 17篇 |
1969年 | 21篇 |
1968年 | 17篇 |
排序方式: 共有2328条查询结果,搜索用时 1 毫秒
81.
The goal of this research is to identify positive practices used when conducting community‐based research with people living with vulnerable conditions. Community‐based research practitioners who participated in the research included 37 researchers, community partners, program planners, and government employees, working in health, human services, children and youth, and education sectors. Concept mapping, a participatory stakeholder‐driven process, was used to generate a framework of how community‐based research practitioners responded to the complex environments of people living with vulnerable conditions when conducting research. Respondents generated positive practices, determined relationships among practices, and rated practices on frequency of use and perceived effectiveness. This study revealed 7 clusters of positive practices: ethical practices, participant supports, social accountability, community involvement, language competence, financial compensation, and project management. 相似文献
82.
Claudio G. Brunstein Corey S. Cutler Todd E. DeFor Haesook Kim Nelli Bejanyan Alfred Garfall Michael R. Verneris Yi-Bin Chen Erica D. Warlick Thomas Spitzer Jeffrey S. Miller Joseph H. Antin Daniel J. Weisdorf Robert Soiffer John E. Wagner Karen K. Ballen 《Biology of blood and marrow transplantation》2017,23(1):126-133
We studied the effect of HLA-C matching in 515 patients after double umbilical cord blood (UCB) transplantation. After HLA matching HLA-A, -B, and -DRB1 at the allele level, we scored patients according to number of donor-recipient HLA-C matches at 4 possible loci: 2 from each donor unit, at the allele level. Given a direct interaction between HLA-A, -B, and -DRB1 matching and HLA-C score, we analyzed HLA-C matching in those receiving at least 1 2/6 to 4/6 HLA–matched unit (n?=?389) versus those receiving only 5/6 or 6/6–matched units (n?=?126). In those with at least 1 2/6 to 4/6 HLA–matched unit, a better HLA-C matching score was associated with significantly lower risk of death of any cause and nonrelapse mortality and better disease-free survival. There was no association with the risk of relapse, acute and chronic graft-versus-host disease, and hematopoietic recovery. In contrast, among patients receiving only allele-level 5/6 or 6/6 HLA–matched UCB units, HLA-C match had no demonstrable effect on any outcome. For patients receiving at least 1 allele-level 2/6 to 4/6 HLA–matched UCB unit, matching at HLA-C reduces nonrelapse mortality and improves survival. 相似文献
83.
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. 总被引:1,自引:0,他引:1
Torsten Trowe Sotiria Boukouvala Keith Calkins Richard E Cutler Ryan Fong Roel Funke Steven B Gendreau Yong D Kim Nicole Miller John R Woolfrey Valentina Vysotskaia Jing Ping Yang Mary E Gerritsen David J Matthews Peter Lamb Timothy S Heuer 《Clinical cancer research》2008,14(8):2465-2475
PURPOSE: Mutations associated with resistance to kinase inhibition are an important mechanism of intrinsic or acquired loss of clinical efficacy for kinase-targeted therapeutics. We report the prospective discovery of ErbB2 mutations that confer resistance to the small-molecule inhibitor lapatinib. EXPERIMENTAL DESIGN: We did in vitro screening using a randomly mutagenized ErbB2 expression library in Ba/F3 cells, which were dependent on ErbB2 activity for survival and growth. RESULTS: Lapatinib resistance screens identified mutations at 16 different ErbB2 amino acid residues, with 12 mutated amino acids mapping to the kinase domain. Mutations conferring the greatest lapatinib resistance cluster in the NH2-terminal kinase lobe and hinge region. Structural computer modeling studies suggest that lapatinib resistance is caused by multiple mechanisms; including direct steric interference and restriction of conformational flexibility (the inactive state required for lapatinib binding is energetically unfavorable). ErbB2 T798I imparts the strongest lapatinib resistance effect and is analogous to the epidermal growth factor receptor T790M, ABL T315I, and cKIT T670I gatekeeper mutations that are associated with clinical drug resistance. ErbB2 mutants associated with lapatinib resistance transformed NIH-3T3 cells, including L755S and T733I mutations known to occur in human breast and gastric carcinomas, supporting a direct mechanism for lapatinib resistance in ErbB2-driven human cancers. The epidermal growth factor receptor/ErbB2/vascular endothelial growth factor receptor inhibitor EXEL-7647 was found to inhibit almost all lapatinib resistance-associated mutations. Furthermore, no ErbB2 mutations were found to be associated with EXEL-7647 resistance and lapatinib sensitivity. CONCLUSIONS: Taken together, these data suggest potential target-based mechanisms of resistance to lapatinib and suggest that EXEL-7647 may be able to circumvent these effects. 相似文献
84.
85.
Computer-assisted reconstructions of small parts of the macular neural network show how the nerve terminals and receptive fields are organized in 3-dimensional space. This biological neural network is anatomically organized for parallel distributed processing of information. Processing appears to be more complex than in computer-based neural networks, because spatiotemporal factors figure into synaptic weighting. Serial reconstruction data show anatomical arrangements which suggest that 1) assemblies of cells analyse and distribute information with inbuilt redundancy, to improve reliability; 2) feedforward/feedback loops provide the capacity for presynaptic modulation of output during processing; 3) constrained randomness in connectivities contributes to adaptability; and 4) local variations in network complexity permit differing analyses of incoming signals to take place simultaneously. The last inference suggests that there may be segregation of information flow to central stations subserving particular functions. 相似文献
86.
87.
Hossain M Jhee SS Shiovitz T McDonald C Sedek G Pommier F Cutler NR 《Clinical pharmacokinetics》2002,41(3):225-234
OBJECTIVE: To investigate the bioavailability of rivastigmine, an approved therapy for patients with mild to moderate dementia of the Alzheimer's type, at the highest approved single dose of 6 mg. DESIGN AND SETTING: Randomised, two-period crossover, single-centre, non-blinded, inpatient study.Patients and participants: Eleven patients (five females and six males) with mean age 69.5 years. METHODS: The 6 mg oral dose was compared with a 2 mg intravenous dose of rivastigmine infused over a 1-hour period. Plasma concentrations of rivastigmine and its metabolite NAP 226-90 were measured with a gas chromatographic/mass spectrometric method. RESULTS: Following oral administration of a single 6 mg capsule, rivastigmine is rapidly absorbed with an average time to peak plasma concentration of about 1 hour and an average peak concentration of about 25.6 g/L. By a noncompartmental approach, the absolute bioavailability of the 6 mg oral dose of rivastigmine was 71.7% when compared with a 2mg intravenous infusion normalised for dose. By using a population pharmacokinetic model with Michaelis-Menten elimination, absolute bioavailability was estimated at 60.2%. The average terminal elimination half-life of rivastigmine ranged from 1.4 to 1.7 hours for both treatments. Plasma concentrations of the major metabolite, NAP 226-90, formed by the hydrolysis of rivastigmine by cholinesterase are lower than those of the parent compound following oral and intravenous administration. CONCLUSION: A noncompartmental approach and a compartmental approach based on a population pharmacokinetic model with Michaelis-Menten elimination yielded comparable values, 71.7% and 60.2% respectively, for the absolute bioavailability of a single 6 mg oral dose of rivastigmine. Comparison with previous studies confirmed that the oral form of the drug exhibits increased bioavailability with increasing dose, consistent with its nonlinear pharmacokinetics.. 相似文献
88.
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin 总被引:5,自引:0,他引:5 下载免费PDF全文
Kosoglou T Meyer I Veltri EP Statkevich P Yang B Zhu Y Mellars L Maxwell SE Patrick JE Cutler DL Batra VK Affrime MB 《British journal of clinical pharmacology》2002,54(3):309-319
AIMS: The primary aims of these two single-centre, randomized, evaluator-blind, placebo/positive-controlled, parallel-group studies were to evaluate the potential for pharmacodynamic and pharmacokinetic interaction between ezetimibe 0.25, 1, or 10 mg and simvastatin 10 mg (Study 1), and a pharmacodynamic interaction between ezetimibe 10 mg and simvastatin 20 mg (Study 2). Evaluation of the tolerance of the coadministration of ezetimibe and simvastatin was a secondary objective. METHODS: Eighty-two healthy men with low-density lipoprotein cholesterol (LDL-C) >or=130 mg dl-1 received study drug once daily in the morning for 14 days. In Study 1 (n=58), five groups of 11-12 subjects received simvastatin 10 mg alone, or with ezetimibe 0.25, 1, or 10 mg or placebo. In Study 2 (n=24), three groups of eight subjects received simvastatin 20 mg alone, ezetimibe 10 mg alone, or the combination. Blood samples were collected to measure serum lipids in both studies. Steady-state pharmacokinetics of simvastatin and its beta-hydroxy metabolite were evaluated in Study 1 only. RESULTS: In both studies, reported side-effects were generally mild, nonspecific, and similar among treatment groups. In Study 1, there were no indications of pharmacokinetic interactions between simvastatin and ezetimibe. All active treatments caused statistically significant (P<0.01) decreases in LDL-C concentration vs placebo from baseline to day 14. The coadministration of ezetimibe and simvastatin caused a dose-dependent reduction in LDL-C and total cholesterol, with no apparent effect on high-density lipoprotein cholesterol (HDL-C) or triglycerides. The coadministration of ezetimibe 10 mg and simvastatin 10 mg or 20 mg caused a statistically (P<0.01) greater percentage reduction (mean -17%, 95% CI -27.7, -6.2, and -18%, -28.4, -7.4, respectively) in LDL-C than simvastatin alone. CONCLUSIONS: The coadministration of ezetimibe at doses up to 10 mg with simvastatin 10 or 20 mg daily was well tolerated and caused a significant additive reduction in LDL-C compared with simvastatin alone. Additional clinical studies to assess the efficacy and safety of coadministration of ezetimibe and simvastatin are warranted. 相似文献
89.
90.
Ojogho O Sahney S Cutler D Abdelhalim F Hasan M Baron P Concepcion W 《The American surgeon》2002,68(12):1115-1119
Despite improving overall results of pediatric renal transplantation children under 5 years of age remain a high-risk group with poorer outcomes often because of a higher rate of surgical complications. This retrospective report details a 12-year experience at a single center and examines the outcome in this high-risk group of patients. We reviewed the medical records of 21 children under 5 years of age who received renal transplantation at Loma Linda University Medical Center between July 1988 and August 2000. The patients were evaluated regularly by the same pediatric nephrologist throughout the study period at our outpatient clinic. Mean recipient age was 3 +/- 1.2 (range 2-5) years; weight at transplantation was 13.3 +/- 5.4 kg. Ten (48%) patients received living related donor (LRD) kidneys and 11 (52%) received cadaver (CAD) kidneys. Mean donor ages for CAD and LRD were 14.4 +/- 10 years and 26.6 +/- 4.9 years, respectively. The mean cold ischemia time (CAD only) was 23.3 +/- 10.6 hours. Renal dysplasia (n = 8) and obstructive uropathy (n = 5) were the most common primary diagnoses. Maintenance immunosuppression consisted of Azathioprine or mycophenolate mofetil (MMF), cyclosporine or tacrolimus and prednisone. Mean follow-up was 80.1 +/- 51.4 months. Twelve (57%) grafts have a follow-up >5 years. Patient survival was 100 per cent. Overall graft survival at one, 3, 5, and 10 years were 95, 95, 88, and 88 per cent respectively. Graft survival for LRD recipients was 100 per cent. No graft was lost as a result of a technical problem or vascular thrombosis. One graft each was lost because of delayed graft function complicated by severe cytomegalovirus infection and chronic rejection. At one year the mean serum creatinine was 0.6 +/- 0.2 mg/dL with a mean calculated glomerular filtration rate of 93 +/- 32 mL/min. All 17 children who are now of school age are attending school. We conclude that excellent rehabilitation and superior long-term patient and graft survival can be achieved with renal transplantation in children of this age group with the use of good surgical techniques and close follow-up. 相似文献